The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Merus N.V(NASDAQ:MRUS) 
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with...
Website: http://www.merus.nl
Founded: 2003
Full Time Employees: 87
Sector: Healthcare
Industry: Biotechnology
Merus N.V Days Payable Outstanding ttm (DPO)
Merus N.V Days Receivable Outstanding ttm (DSO)
Merus N.V Days Inventory Outstanding ttm (DIO)
Merus N.V Op Cashflow Per Share ttm
Merus N.V Free Cashflow Per Share ttm
Merus N.V Cash Per Share ttm
Merus N.V P/S ratio ttm
Merus N.V (GAAP) P/E ratio ttm
Merus N.V P/B ratio ttm
No extra charts and metrics for this ticker.